Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
8455321
Reference Type
Journal Article
Subtype
Review
Title
Flavonoids nanoparticles in cancer: Treatment, prevention and clinical prospects
Author(s)
Khan, H; Ullah, H; Martorell, M; Valdes, SE; Belwal, T; Tejada, S; Sureda, A; Kamal, MA; ,
Year
2021
Is Peer Reviewed?
1
Journal
Seminars in Cancer Biology
ISSN:
1044-579X
EISSN:
1096-3650
Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
Location
LONDON
Volume
69
Page Numbers
200-211
Language
English
PMID
31374244
DOI
10.1016/j.semcancer.2019.07.023
Web of Science Id
WOS:000625461400001
URL
https://linkinghub.elsevier.com/retrieve/pii/S1044579X19301828
Exit
Abstract
The conventional therapies for cancer have a major concern of poor accessibility to tumor tissues. Furthermore, the requirement of higher doses and non-selective nature of therapeutic are associated with a range of adverse drug reactions (ADRs). However, flavonoids are documented to be effective against various types of cancer, but they are not evaluated for their safety profile and tumor site-specific action. Low solubility, rapid metabolism and poor absorption of dietary flavonoids in gastrointestinal tract hinder their pharmacological potential. Some studies have also suggested that flavonoids may act as pro-oxidant in some cases and may interact with other therapeutic agents, especially through biotransformation. Nanocarriers can alter pharmacokinetics and pharmacodynamic profile of incorporating drug. Moreover, nanocarriers are designed for targeted drug delivery, improving the bioavailability of poorly water-soluble drugs, delivery of macromolecules to site of action within the cell, combining therapeutic agents with imaging techniques which may visualize the site of drug delivery and co-delivery of two or more drugs. Combining two or more anti-cancer agents can reduce ADRs and nanotechnology played a pivotal role in this regard. In vitro and in vivo studies have shown the potential of flavonoids nano-formulations, especially quercetin, naringenin, apigenin, catechins and fisetin in the prevention and treatment of several types of cancer. Similarly, clinical trials have been conducted using flavonoids alone or in combination, however, the nano-formulations effect still needs to be elucidated. This review focuses on the impact of flavonoids nano-formulations on the improvement of their bioavailability, therapeutic and safety profile and will open new insights in the field of drug discovery for cancer therapeutics.
Keywords
Cancer therapeutics; Drug discovery; Flavonoids; Nanoparticles
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity